In type 2 diabetes, dipeptidyl peptidase-4 inhibitors do not increase pancreatitis

被引：1
作者：
Morey-Vargas, Oscar L. [1 ]
Montori, Victor M. [1 ]
机构：
[1] Mayo Clin, Rochester, MN 55905 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2014年 / 160卷 / 02期
关键词：
THERAPIES;
D O I：
10.7326/0003-4819-160-2-201401210-02008
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 4 条
  • [1] Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
    Aschner, Pablo
    Kipnes, Mark S.
    Lunceford, Jared K.
    Sanchez, Matilde
    Mickel, Carolyn
    Williams-Herman, Debora E.
    [J]. DIABETES CARE, 2006, 29 (12) : 2632 - 2637
  • [2] Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies
    Elashoff, Michael
    Matveyenko, Aleksey V.
    Gier, Belinda
    Elashoff, Robert
    Butler, Peter C.
    [J]. GASTROENTEROLOGY, 2011, 141 (01) : 150 - 156
  • [3] Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
    Monami, M.
    Ahren, B.
    Dicembrini, I.
    Mannucci, E.
    [J]. DIABETES OBESITY & METABOLISM, 2013, 15 (02) : 112 - 120
  • [4] Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus A Population-Based Matched Case-Control Study
    Singh, Sonal
    Chang, Hsien-Yen
    Richards, Thomas M.
    Weiner, Jonathan P.
    Clark, Jeanne M.
    Segal, Jodi B.
    [J]. JAMA INTERNAL MEDICINE, 2013, 173 (07) : 534 - 539
1